Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H2 2018, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechani...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H2 2017, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechani...

Summary

The colorectal cancer (CRC) market, considering the sales of both branded treatments and generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence, and the launch and uptake of premium-priced therapies. Traditionally, the CRC market has been dominated by two therapeutic classes: angiogenesis and EGFR inhibitors. However, the efficacy of these agents is limited by the insurgence of acquired resistance. Further, RAS mutant patients, who are not eligible to EGFR inhibitors, have a lower number of available treatment options and usually receive fewer lines of treatment compared with patients with RAS wild-type disease. The CRC competitive landscape is going to experience a substantial change, following the approval of pipeline agents exploiting novel mechanisms of actions, especially immunotherapy. Some pipeline drug developers have invested heavily in the identification of potential predictive biomarkers; therefore, these novel agents are ex...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatic - Colorectal Metastasis – Pipeline Review, H1 2017, provides an overview of the Hepatic - Colorectal Metastasis (Oncology) pipeline landscape.

Patients who present with hepatic colorectal metastases are usually asymptomatic. Symptoms such as abdominal pain and weight loss are associated with advanced (high-volume) metastases and a poor prognosis. Although liver resection is not the primary treatment for most patients with hepatic colorectal metastases, appropriate liver resection is the standard of care for treatment of patients with isolated hepatic colorectal metastases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatic - Colorectal Metastasis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatic - Colorectal Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), rout...

Summary

Colorectal cancer (CRC) is a cancer that starts in the colon or the rectum (ACS, 2016). CRC is one of the most common types of cancers diagnosed. For this analysis, GlobalData epidemiologists defined CRC as a cancer in all sub-sites of the colon and rectum, using the International Classification of Diseases, Tenth Revision (ICD-10) codes for CRC (C18-C20). To build the forecast, GlobalData epidemiologists sourced international and national cancer databases such as the Cancer Incidence in Five Continents (CI5) CI5plus data analysis tool; the EUROCARE-5 survival database; Surveillance, Epidemiology and End Results (SEER); the German Centre for Cancer Registry (ZfKD); peer-reviewed research articles; and government publications. The forecast methodology is consistent across each of the eight markets, thereby allowing for a meaningful comparison among them.

In 2015, there were 746,590 diagnosed incident cases of CRC in the 8MM. GlobalData epidemiologists forecast that the diagnosed incident cases in the 8MM will increase to 913,832 by 2025 at an Annual Gro...